Clinical Trial Update: Rituximab in Treating Patients With Peripheral Neuropathy Caused by Monoclonal Gammopathy of Undetermined Significance [Phase 2]

View source ↗

Summary

Phase 2 trial of rituximab in patients with peripheral neuropathy caused by monoclonal gammopathy of undetermined significance was terminated; results posted in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Monoclonal Gammopathy of Undetermined Significance
• Peripheral Neuropathy

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: Mayo Clinic | Conditions: Precancerous Condition | Phase 2 | Status: TERMINATED | Results posted: 2014-05-06